Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
Overview | Financials
Company Name | Arcutis Biotherapeutics, Inc. |
Symbol | ARQT |
Currency | USD |
Price | 8.72 |
Market Cap | 1,019,289,520 |
Dividend Yield | 0% |
52-week-range | 1.76 - 13.17 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Todd Franklin Watanabe M.A. |
Website | https://www.arcutis.com |
An error occurred while fetching data.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD